Jorge Mouro

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.

S. Ailawadhi, Shien Guo, S. Abouzaid, 2017, Clinical therapeutics.

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

D. Siegel, W. Pierceall, S. Srinivasan, 2019, British journal of haematology.

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

D. Siegel, D. Reece, A. Agarwal, 2022, Leukemia & lymphoma.

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

D. Reece, A. Agarwal, G. Schiller, 2017 .

Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.

M. Dimopoulos, X. Leleu, M. Delforge, 2023, Clinical lymphoma, myeloma & leukemia.

The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry.

R. Rifkin, R. Abonour, J. Omel, 2024, Clinical lymphoma, myeloma & leukemia.